Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

Fineline Cube May 23, 2025

French pharmaceutical firm Servier announced a definitive agreement to acquire BN104 from BioNova Pharmaceuticals (Shanghai)...

Company Drug

ImmuneOnco and Instil Bio Announce Clinical Updates for IMM2510 in NSCLC

Fineline Cube May 23, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) and its US partner Instil Bio Inc...

Company Drug Policy / Regulatory

UCB’s Keppra Procurement Resumed in Shanghai After Regulatory Halt

Fineline Cube May 23, 2025

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification resuming the procurement of UCB’s...

Company Deals

RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion

Fineline Cube May 23, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares...

Company Drug

Ascletis Pharma Starts Phase I Study of ASC50 for Psoriasis in the US

Fineline Cube May 23, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has received approval from the US...

Company Drug

Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC

Fineline Cube May 23, 2025

China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...

Company

AstraZeneca Shuts Down Neuroscience Research Group to Focus on Core Areas

Fineline Cube May 23, 2025

AstraZeneca (AZ; NASDAQ: AZN) confirmed the closure of its neuroscience research group during its 2025...

Company Drug

Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes

Fineline Cube May 23, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...

Company Drug

Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy

Fineline Cube May 23, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...

Company Deals

Joincare Pharmaceutical Plans to Acquire 64.81% Stake in Imexpharm for USD 220M

Fineline Cube May 23, 2025

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced plans to acquire a 64.81%...

Company Drug

Chongqing Genrix Bio’s GR2001 Tetanus Monoclonal Antibody NDA Accepted by NMPA

Fineline Cube May 23, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) recently announced that its New Drug...

Company Medical Device

Medtronic Plans to Spin Off Diabetes Business into Publicly Traded Entity

Fineline Cube May 23, 2025

Medtronic plc (NYSE: MDT), the US-headquartered medical technology company, has unveiled plans to spin off...

Company Drug

Bayer Launches Phase I Study of BAY 3670549 for Atrial Fibrillation

Fineline Cube May 23, 2025

German pharmaceutical giant Bayer (ETR: BAYN) this week initiated a Phase I clinical study for...

Company Drug

InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment

Fineline Cube May 23, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...

Company Drug

Uni-Bio Science’s Generic Diquas Accepted for NMPA Review

Fineline Cube May 23, 2025

China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...

Company Drug

MicusRx’s Contezolid Sodium NDA Accepted for Review by NMPA

Fineline Cube May 23, 2025

China-based Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) announced that a New Drug Application (NDA)...

Company Deals

Sanofi to Acquire Vigil Neuroscience to Boost Neurology Pipeline

Fineline Cube May 23, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) is set to acquire US-based Vigil Neuroscience, Inc., a...

Company Drug

Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment

Fineline Cube May 23, 2025

The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...

Company Deals

Shanghai INT Medical Instruments to Acquire Majority Stake in Endonom Medical

Fineline Cube May 22, 2025

China-based Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) is set to jointly acquire a...

Company

Medtronic Reports Q4 and FY2025 Results with Revenue Growth Across Key Segments

Fineline Cube May 22, 2025

US-Irish firm Medtronic (NYSE: MDT) released financial results for its fourth quarter (Q4) and fiscal...

Posts pagination

1 … 153 154 155 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.